홈 › 급성 이표형 백혈병 › 텍사스
텍사스의 급성 이표형 백혈병 임상 시험
급성 이표형 백혈병 관련 연구 13개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.
텍사스의 도시
공식 연구 텍스트(영어)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1상
12세 ~ 78세 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 외 7개
피험자 모집 중2상
365 Days · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06317662Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT03683433The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 외 10개
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- 외 12개
피험자 모집 중3상
365 Days – 25 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT03959085Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
13세 ~ 90세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- UT Southwestern/Simmons Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
피험자 모집 중1상
1세 ~ 30세 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06177067Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
피험자 모집 중2상
15세 ~ 80세 · 모든 성별 · 2026. 7. 30. 업데이트됨 · NCT02727803A Study of Revumenib and Mezigdomide in People With Leukemia
- MD Anderson Cancer Center (Data Collection Only), Houston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 6. 22. 업데이트됨 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 12. 업데이트됨 · NCT04047641Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- M D Anderson Cancer Center, Houston
피험자 모집 중2상
18세 ~ 65세 · 모든 성별 · 2026. 5. 20. 업데이트됨 · NCT02115295The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
피험자 모집 중1/2상
12세 ~ 95세 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT04329728Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- University of Texas, Southwestern, Dallas
- Cook Children's Hospital, Fort Worth
- Texas Children's Hospital/Baylor College of Medicine, Houston
피험자 모집 중1상
1세 ~ 21세 · 모든 성별 · 2024. 12. 6. 업데이트됨 · NCT05476770ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.